Inventor · disambiguated record
Karl-Josef Kallen
Also filed as: KALLEN KARL-JOSEF
29 granted patents·22 pending applications·730 citations·filing 2009–2025
98Inventor score
Top patents by PatentIndex Score
51 records- 0199US10434158B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2018·Granted Oct 8, 2019·31 cites·21 claims
- 0299US10117920B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2018·Granted Nov 6, 2018·32 cites·12 claims
- 0398US11458195B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2019·Granted Oct 4, 2022·12 cites·25 claims
- 0498US11266735B2Combination vaccineCUREVAC AG·Filed 2020·Granted Mar 8, 2022·40 cites·17 claims
- 0598US10729761B2Vaccination in newborns and infantsCUREVAC AG·Filed 2019·Granted Aug 4, 2020·30 cites·20 claims
- 0698US10596252B2Vaccination in newborns and infantsCUREVAC AG·Filed 2018·Granted Mar 24, 2020·30 cites·19 claims
- 0798US10588959B2Combination vaccineCUREVAC AG·Filed 2016·Granted Mar 17, 2020·30 cites·25 claims
- 0898US10293058B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2016·Granted May 21, 2019·50 cites·16 claims
- 0998US10172935B2Vaccination in newborns and infantsCUREVAC AG·Filed 2017·Granted Jan 8, 2019·33 cites·16 claims
- 1097US11110157B2Combination of vaccination and OX40 agonistsCUREVAC AG·Filed 2019·Granted Sep 7, 2021·28 cites·13 claims
- 1197US10918740B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2018·Granted Feb 16, 2021·38 cites·19 claims
- 1297US10568958B2Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugatesCUREVAC AG·Filed 2016·Granted Feb 25, 2020·30 cites·12 claims
- 1397US10307472B2Combination of vaccination and OX40 agonistsCUREVAC AG·Filed 2014·Granted Jun 4, 2019·31 cites·13 claims
- 1497US9974845B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2014·Granted May 22, 2018·32 cites·10 claims
- 1597US8968746B2Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulationBAUMHOF PATRICK·Filed 2011·Granted Mar 3, 2015·70 cites·16 claims
- 1696US10869935B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2019·Granted Dec 22, 2020·29 cites·23 claims
- 1796US9623095B2Vaccination in newborns and infantsKALLEN KARL-JOSEF·Filed 2012·Granted Apr 18, 2017·74 cites·15 claims
- 1894US9890391B2RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loopCUREVAC GMBH·Filed 2013·Granted Feb 13, 2018·30 cites·16 claims
- 1994US9421255B2Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugatesBAUMHOF PATRICK·Filed 2012·Granted Aug 23, 2016·34 cites·19 claims
- 2093US11690910B2Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigenCureVac SE·Filed 2019·Granted Jul 4, 2023·6 cites·20 claims
- 2193US11458193B2Combination of vaccination and inhibition of MHC class I restricted antigen presentationCUREVAC AG·Filed 2017·Granted Oct 4, 2022·11 cites·10 claims
- 2291US2025345411A1Vaccination in newborns and infantsCureVac SE·Filed 2025·Application pending·0 cites
- 2390US12036277B2Vaccination with mRNA-coded antigensCureVac SE·Filed 2024·Granted Jul 16, 2024·0 cites·24 claims
- 2489US9737595B2Combination of vaccination and inhibition of MHC class I restricted antigen presentationLORENZ CHRISTINA·Filed 2011·Granted Aug 22, 2017·29 cites·16 claims
- 2589US2024390478A1Vaccination in elderly patientsCureVac SE·Filed 2024·Application pending·0 cites
- 2688US12390520B2Vaccination in newborns and infantsCureVac SE·Filed 2023·Granted Aug 19, 2025·0 cites·47 claims
- 2786US2025302932A1Combination of vaccination and ox40 agonistsCureVac SE·Filed 2024·Application pending·0 cites
- 2884US12447209B2Combination of vaccination and inhibition of the PD-1 pathwayCureVac SE·Filed 2022·Granted Oct 21, 2025·0 cites·35 claims
- 2981US2025360196A1Combination vaccineCureVac SE·Filed 2025·Application pending·0 cites
- 3081US2025213724A1Rna containing composition for treatment of tumor diseasesCureVac SE·Filed 2025·Application pending·0 cites
- 3181US2023338579A1Rna containing composition for treatment of tumor diseasesCureVac SE·Filed 2022·Application pending·0 cites
- 3280US12337031B2Combination vaccineCUREVAC AG·Filed 2022·Granted Jun 24, 2025·0 cites·24 claims
- 3378US2025345410A1Vaccination in newborns and infantsCureVac SE·Filed 2025·Application pending·0 cites
- 3476US12178863B2Combination of vaccination and OX40 agonistsCUREVAC AG·Filed 2021·Granted Dec 31, 2024·0 cites·14 claims
- 3575US11672856B2Vaccination in newborns and infantsCUREVAC AG·Filed 2020·Granted Jun 13, 2023·0 cites·31 claims
- 3675US2019151438A1VACCINATION WITH mRNA-CODED ANTIGENSCUREVAC AG·Filed 2019·Application pending·0 cites
- 3775US2023285594A1Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulationCureVac SE·Filed 2022·Application pending·0 cites
- 3874US2021030866A1Vaccination in newborns and infantsCUREVAC AG·Filed 2020·Application pending·0 cites
- 3972US2021023199A1VACCINATION WITH mRNA-CODED ANTIGENSCUREVAC AG·Filed 2020·Application pending·0 cites
- 4070US11975064B2Vaccination with mRNA-coded antigensCureVac SE·Filed 2017·Granted May 7, 2024·0 cites·24 claims
- 4170US2017266268A1Vaccination in newborns and infantsCUREVAC AG·Filed 2017·Application pending·0 cites
- 4266US2016206719A1Combination of vaccination and inhibition of the pd-1 pathwayCUREVAC AG·Filed 2016·Application pending·0 cites
- 4366US2016151474A1Vaccination in elderly patientsCUREVAC AG·Filed 2016·Application pending·0 cites
- 4464US2013295043A1Vaccination in elderly patientsKALLEN KARL-JOSEF·Filed 2012·Application pending·0 cites
- 4563US2018207295A1Rna containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2018·Application pending·0 cites
- 4658US2015118264A1Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigenCUREVAC GMBH·Filed 2013·Application pending·0 cites
- 4757US2010330029A1Cancer Treatments with Radiation and ImmunocytokinesMERCK PATENT GMBH·Filed 2009·Application pending·0 cites
- 4856US2015258214A1Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulationCUREVAC GMBH·Filed 2015·Application pending·0 cites
- 4945US2015037326A1Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigenBAYER INNOVATION GMBH·Filed 2013·Application pending·0 cites
- 5037US2016166668A1Composition and vaccine for treating prostate cancerCUREVAC AG·Filed 2016·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →